EP3587440A1 - Menschliches pd-l1-peptid mit hoher proteinaffinität und verwendung davon - Google Patents

Menschliches pd-l1-peptid mit hoher proteinaffinität und verwendung davon Download PDF

Info

Publication number
EP3587440A1
EP3587440A1 EP18757780.4A EP18757780A EP3587440A1 EP 3587440 A1 EP3587440 A1 EP 3587440A1 EP 18757780 A EP18757780 A EP 18757780A EP 3587440 A1 EP3587440 A1 EP 3587440A1
Authority
EP
European Patent Office
Prior art keywords
peptide
protein
seq
human
pplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18757780.4A
Other languages
English (en)
French (fr)
Other versions
EP3587440A4 (de
EP3587440B1 (de
Inventor
Baoxiu LIU
Naishuo Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3587440A1 publication Critical patent/EP3587440A1/de
Publication of EP3587440A4 publication Critical patent/EP3587440A4/de
Application granted granted Critical
Publication of EP3587440B1 publication Critical patent/EP3587440B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of biotechnology.
  • the invention specifically relates to a peptide having high affinity for PD-L1 protein, and use thereof.
  • Tumor is a serious disease that threatens human health and is difficult to prevent effectively.
  • the main methods for treating tumors include radiotherapy, chemotherapy and surgical treatment, but the therapeutic effect thereof is not satisfying, and the 5-year survival rate after surgery is low.
  • development of an effective drug for the treatment of tumors is a hot topic in cancer research.
  • immune checkpoint therapy represented by anti-PD-1/PD-L1 has been explored as a new approach for tumor treatment.
  • Three PD-1/PD-L1 antibody drugs have been approved by the US Food and Drug Administration (FDA) for clinical treatment. Although these drugs have certain effects, they have drawbacks such as low efficiency, side effects and off-target. Therefore, it is urgent to develop a drug that is efficient, long-lasting and has a wide range of therapeutic effects.
  • the target peptide of the invention is obtained by chemical synthesis and purification.
  • the dissociation constant between the peptide and PD-L1 protein is determined by ELISA, and the blocking effect of the peptide on PD-1/PD-L1 signaling pathway is determined.
  • the affinity of the peptide for PD-L1 protein expressed on the surface of tumor cells was detected by flow cytometry. Finally, the peptide is infused into a mouse tumor model, and the potential value of the peptide in treating tumor is confirmed by the changes in tumor size and survival time of the mouse.
  • the object of the present invention is to provide a peptide having high binding affinity for PD-L1 protein and use of the peptide in treatment of tumor.
  • the present disclosure provides a peptide having high affinity for human PD-L1 protein (referred to as PPLC), wherein the peptide has an amino acid sequence as set forth in SEQ.ID.NO.1.
  • the peptide has the following functional characteristics: (1) a high affinity for human PD-L1 protein, with a dissociation constant Kd of 0.75 ⁇ M (Kd value indicates the concentration of ligand when half of the receptors are bound by the ligand, and the smaller the Kd value, the higher the affinity of the receptor to the ligand); (2) it can effectively block the affinity of PD-1/PD-L1 protein; (3) it can effectively binds to PD-L1 protein expressed on the cell surface; (4) infusion of the peptide into tumor-injected animals can effectively inhibit tumor growth and extend the survival time of animals.
  • the present disclosure also provides a gene encoding the peptide having high affinity for human PD-L1 protein (consisting of degenerate codons of the corresponding amino acids), wherein the gene has a nucleotide sequence as set forth in SEQ. ID. NO. 2.
  • the present disclosure also obtains, by biotechnological means, a series of peptide sequences having the same function as the peptide represented by SEQ.ID.NO.1, wherein the peptide sequences mainly include SEQ.ID.NO.3 and SEQ.ID.NO.4.
  • the present disclosure also provides a peptide, comprising amino acid sequences of peptides having high affinity for PD-L1 protein as set forth in SEQ.ID.NO.1, SEQ.ID.NO.3 and SEQ.ID.NO.4, wherein the peptide is a single repeated or multiple repeated tandem or branched peptide molecular sequence, and a molecular comprising these core sequences (i.e., having a homology of more than 70%), wherein the molecular has an amino acid sequence as set forth in SEQ.ID.NO.5.
  • the present disclosure also provides a peptide modified by biological or chemical group, comprising SEQ.ID.NO.1, SEQ.ID.NO.3 or SEQ.ID.NO.4 of the peptide having high affinity for PD-L1 protein as a core sequence, and its C-terminal (N-terminal or a side-chain group) is linked to an antigen or a drug, or modified by PEG or covalently modified by other molecular groups.
  • the present disclosure also provides a modified peptide, comprising the above peptide having high affinity for PD-L1 protein, which is labeled with a FITC fluorophore, an isotope, a chemiluminescent group or an enzyme reagent, and the modified peptide can be used for PD-L1 protein detection.
  • the present disclosure also provides the use of the above peptide having high affinity for PD-L1 protein in preparation of a PD-L1 protein antagonist.
  • the present disclosure also provides the use of the above peptide having high affinity for PD-L1 protein in preparation of an agent for detection or for clinical testing of PD-L1 protein expression.
  • the present disclosure also provides the use of a gene having nucleotide sequence as set forth in SEQ. ID NO. 2 in preparation of a PD-L1 protein antagonist or preparation of an agent for tracer detection of PD-L1 protein.
  • the peptide of the present invention having the amino acid sequence of SEQ.ID.NO.1 can be used as a PD-L1 protein antagonist drug.
  • the peptide has a high binding affinity for PD-L1 protein, blocks the negative regulatory signaling pathway PD-1/PD-L1 of human immunity and thus activates immunity, initiates the killing effect of T cells on tumors, and can be used as a potential drug for tumor targeted therapy.
  • the peptide of present invention having the amino acid sequence of SEQ.ID.NO.3 or SEQ.ID.NO.4 can also be used as an antagonist of PD-L1 protein. These peptides also have a high binding affinity for PD-L1 protein, block the affinity of PD-1/PD-L1 and initiate immunity to kill tumor cells.
  • a 96-well ELISA plate was coated with 2 ⁇ g/ml PD-L1 protein at 4 °C overnight.
  • Different concentrations of PPLC peptide labeled with FITC were added to each well and incubated for 1 h.
  • HRP-conjugated anti-FITC antibody was added, incubated for 1 h, and then ABTS coloring solution was added.
  • the OD value at 410 nm was measured using a M5 microplate reader, and GraphPad Prism 6 was used for plotting and analysis.
  • the results demonstrate that PPLC peptide has a strong affinity for PD-L1 protein, with a dissociation constant Kd of 0.75 ⁇ M ( Figure 1 ).
  • a 96-well ELISA plate was coated with 2 ⁇ g/ml PD-L1 protein at 4 °C overnight. Different concentrations of PPLC peptide and 1 ⁇ g/ml PD-1 protein were mixed and incubated together. After incubation, rabbit anti-human PD-1 monoclonal antibody was added as primary antibody, and then HRP-conjugated goat anti-rabbit IgG monoclonal antibody was added as secondary antibody. After ABTS color development, the OD value at 410 nm was measured using a M5 microplate reader, and GraphPad Prism 6 was used for plotting and analysis. The results demonstrate that PPLC peptide can effectively block the binding of PD-1/PD-L1 ( Figure 2 ).
  • Binding assay of PPLC peptide to PD-L1 protein expressed on the cell surface Binding assay of PPLC peptide to PD-L1 protein expressed on the cell surface.
  • the recombinant plasmid expressing recombinant human PD-L1 protein was transfected into CHO cell line and incubated for 36 hours. After incubation, anit-PD-L1 monoclonal antibody or PPLC peptide labeled with FITC was added and incubated at 4 °C for 30 minutes. After incubation, flow cytometry was performed ( Figure 3 ). After transfection of the plasmid, the cells were further cultured for 36 hours, and then the PPLC peptide labeled with FITC was added and incubated at 37 °C for 30 minutes. After incubation, fluorescence confocal detection was performed ( Figure 4 ). The results demonstrate that the PPLC peptide can efficiently bind to the PD-L1 protein expressed on the cell surface ( Figure 3 and Figure 4 ).
  • mice The experimental animals were divided into two groups: PBS group and PPLC group. Tumors were injected subcutaneously into 6 weeks old female Balb/c mice. Two weeks later, when the tumor size reached 100 mm 3 , PPLC drug treatment was performed. The size of the mouse tumor was measured daily and the change was recorded. The results demonstrate that PPLC peptide can significantly reduce the growth rate of mouse tumor ( Figure 5 ) and prolong the survival time of mice ( Figure 6 ).
  • the peptide provided herein has a strong affinity for PD-L1 protein and can block the affinity of PD-1/PD-L1 protein in human.
  • the peptide can break the immune tolerance of tumors, activate immunity, initiate killing effect of T cells on tumors, and achieve the purpose of tumor treatment. Therefore, the peptide can be used as a drug for tumor targeted therapy. Since the PPLC peptide has high affinity for PD-L1 protein, it can be used to prepare a probe for detecting PD-L1 protein.
  • the PPLC peptide When the PPLC peptide is labeled with a FITC fluorophore, an isotope, a chemiluminescent group or an enzyme reagent, it can be used for quantitative, qualitative and location detection of the presence of PD-L1 protein in various biological samples and cells.
  • Desired peptides having an affinity for PD-L1 protein and blocking the affinity of PD-1/PD-L1 protein were artificially synthesized by a chemical method.
  • Lys (Dde)-Wang Resin was soaked in DCM for 10 min, and then DCM was drained. 25% piperidine (piperidine/DMF) with 3-fold volume was added into the resin, and then the piperidine was drained after bubbling with nitrogen for 20 min. DMF was added and blown for 1 min. After 6 cycles, DMF was drained, and the resin was detected to be blue by ninhydrin.
  • the product is H-Lys (Dde)-Wang Resin. Three equivalents of Fmoc-Val-OH, HATU, DIEA in DMF were added to the resin. After blowing for 20 min with nitrogen, the DMF reaction solution was drained. DMF was added and blown for 1 min with nitrogen before draining.
  • the product is Fmoc-Val-Lys (Dde)-Wang Resin.
  • the crude product was obtained by the same method. Purification was carried out on a Hanbang YCM C18 column using acetonitrile and Milli-Q water. In this way, a peptide having high specificity and high activity was obtained.
  • a 96-well ELISA plate was coated with 2 ⁇ g/ml PD-L1 protein at 4 °C overnight. Different concentrations of PPLC peptide labeled with FITC were added to each well and incubated for 1h. After incubation, HRP-conjugated anti-FITC antibody was added, incubated for 1 h, and then ABTS coloring solution was added. The OD value at 410 nm was measured using a M5 microplate reader, and GraphPad Prism 6 was used for plotting and analysis. The results demonstrate that PPLC peptide has a high binding affinity for PD-L1 protein, with a dissociation constant Kd of 0.75 ⁇ M.
  • a 96-well ELISA plate was coated with 2 ⁇ g/ml PD-L1 protein at 4 °C overnight. Different concentrations of PPLC peptide and 1 ⁇ g/ml of PD-1 protein were mixed and incubated together. After incubation, rabbit anti-human PD-1 monoclonal antibody was added as primary antibody, and then HRP-conjugated goat anti-rabbit IgG monoclonal antibody was added as secondary antibody. After ABTS color development, the OD value at 410 nm was measured using a M5 microplate reader, and GraphPad Prism 6 was used for plotting and analysis. The results demonstrate that PPLC peptide can effectively block the binding of PD-1/PD-L1.
  • the recombinant plasmid expressing recombinant human PD-L1 protein was transfected into CHO cell line and incubated for 36 hours. After incubation, anit-PD-L1 monoclonal antibody or PPLC peptide labeled with FITC was added, and incubated at 4 °C for 30 minutes. After incubation, flow cytometry was performed. After transfection of the plasmid, the cells were further cultured for 36 hours, and then the PPLC peptide labeled with FITC was added, and incubated at 37 °C for 30 minutes. After incubation, fluorescence confocal detection was performed. The results demonstrate that the PPLC peptide can efficiently bind to the PD-L1 protein expressed on the cell surface.
  • mice The experimental animals were divided into two groups: PBS group and PPLC group. Tumors were injected subcutaneously into female Balb/c mice. Two weeks later, when the tumor size reached 100 mm 3 , PPLC drug treatment was performed. The size of the mouse tumor was measured daily and the change was recorded. The results demonstrate that PPLC peptide can significantly reduce the growth rate of mouse tumor and prolong the survival time of mice.
  • PPLC peptide has a high binding affinity for PD-L1 protein, and can block the affinity of PD-1/PD-L1 protein at molecular level.
  • Animal results showed that the tumor size of mice treated with PPLC peptide was significantly smaller than that of the control group. The above results indicate that PPLC peptide can break immune tolerance of tumor, improve the killing of tumor cells by T cells, and thus achieve the purpose of treating tumors.
  • Tumor immunotherapy is a new method for treating tumors developed in recent years.
  • Immune checkpoint blockade therapy represented by PD-1/PD-L1 protein is an important component of tumor immunotherapy.
  • some PD-1/PD-L1 antibody-based drugs have been approved by the FDA, and have shown good results in clinical use and in treatment of diseases such as melanoma.
  • antibody therapy also faces many problems such as high immunogenicity, high cost, severe side effects and off-target.
  • the development of an anti-tumor drug with both targeting and small immunogenicity is an important direction in the development of immunology today.
  • the peptide having high binding affinity for PD-L1 protein provided herein can inhibit the binding of PD-1/PD-L1 protein, break immune tolerance of tumor and significantly inhibit the growth of tumor cells.
  • the peptide of the present invention can be used as a potential drug for targeted tumor therapy.
  • the modified PPLC peptide can be used as a detection reagent for detecting the expression of human PD-L1 protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP18757780.4A 2017-02-25 2018-01-25 Menschliches pd-l1-peptid mit hoher proteinaffinität und verwendung davon Active EP3587440B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710105087.2A CN108503691B (zh) 2017-02-25 2017-02-25 一种人pd-l1蛋白高亲和性肽及其应用
PCT/CN2018/074112 WO2018153208A1 (zh) 2017-02-25 2018-01-25 一种人pd-l1蛋白高亲和性肽及其应用

Publications (3)

Publication Number Publication Date
EP3587440A1 true EP3587440A1 (de) 2020-01-01
EP3587440A4 EP3587440A4 (de) 2021-01-13
EP3587440B1 EP3587440B1 (de) 2023-03-15

Family

ID=63254285

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18757780.4A Active EP3587440B1 (de) 2017-02-25 2018-01-25 Menschliches pd-l1-peptid mit hoher proteinaffinität und verwendung davon

Country Status (6)

Country Link
US (1) US11377501B2 (de)
EP (1) EP3587440B1 (de)
JP (1) JP6974874B2 (de)
CN (1) CN108503691B (de)
RU (1) RU2725954C1 (de)
WO (1) WO2018153208A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669102A (zh) * 2019-09-06 2020-01-10 中国药科大学 一种具有免疫检查点拮抗活性的多肽及其应用
CN110746493A (zh) * 2019-09-06 2020-02-04 中国药科大学 一种pd-l1拮抗剂多肽及其应用
CN110669108A (zh) * 2019-09-06 2020-01-10 中国药科大学 一种多肽及其应用
CN111548393B (zh) * 2020-04-27 2021-10-26 贵州民族大学 一种线形肽分子及其应用
CN112402622B (zh) * 2020-11-10 2022-04-01 福建医科大学 靶向pd-l1的抗肿瘤多肽纳米药物载体及其应用
CN116731193A (zh) * 2022-03-01 2023-09-12 伯桢生物科技(杭州)有限公司 重组蛋白及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CA2850245C (en) * 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
CN103936835B (zh) * 2014-04-29 2016-03-30 郑州大学 具有抗肿瘤活性的靶向PD-L1IgV亲和肽D1
EP3169361B1 (de) * 2014-07-15 2019-06-19 F.Hoffmann-La Roche Ag Zusammensetzungen zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und mek-inhibitoren
CN114591420A (zh) * 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽

Also Published As

Publication number Publication date
JP2020508069A (ja) 2020-03-19
WO2018153208A1 (zh) 2018-08-30
EP3587440A4 (de) 2021-01-13
US11377501B2 (en) 2022-07-05
RU2725954C1 (ru) 2020-07-07
US20210230286A1 (en) 2021-07-29
EP3587440B1 (de) 2023-03-15
JP6974874B2 (ja) 2021-12-01
CN108503691B (zh) 2021-07-23
CN108503691A (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3587440B1 (de) Menschliches pd-l1-peptid mit hoher proteinaffinität und verwendung davon
CN108840923B (zh) 一种靶向pd-l1的多肽及其应用
EP2210904A1 (de) Fusionsprotein mit tumornekrosefaktorbedingte apoptose induzierendem ligand und integrin-ligand sowie seine verwendung
CN105121474A (zh) 融合免疫调节蛋白及其制备方法
EA030147B1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
CN102481341A (zh) 蛋白原及其使用方法
CN107519486A (zh) 于感染性与恶性疾病的治疗中提升免疫反应的方法
EP2567983B1 (de) Tumoranzielende tumornekrosefaktor-vermittelte apoptose-liganden-variante und verwendung davon
WO2021247794A2 (en) B7h3-targeting proteins and methods of use thereof
JP2016523558A (ja) 細胞透過性ペプチド、及びそれを含むコンジュゲート
JP2024012517A (ja) がん治療用ペプチドサポリン複合体
CN102898527A (zh) 融合蛋白、药物组合物及预防或治疗癌症的方法
WO2003106499A1 (ja) 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
CN100352832C (zh) 促进毛发生长的寡肽
CN101838306B (zh) 一种k4多肽合成产物及其应用
CN111793134A (zh) 一种用于癌症治疗中的药物、肿瘤疫苗及抑制剂
CN101838305A (zh) 一种t2多肽合成产物及其应用
Huang et al. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD) 3-tTF
CN101838307B (zh) 一种k2多肽合成产物及其应用
WO2017138471A1 (ja) 抗イヌｃｄ７０モノクローナル抗体
US20230192768A1 (en) High-affinity peptide for tumor necrosis factor alpha and application thereof
KR101732380B1 (ko) 상피성장인자 수용체를 표적으로 하는 신규 항암제
CN102391377A (zh) 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CN113717287A (zh) 一种结合TGF-β的双功能抗体融合蛋白
CN107286238B (zh) 抗hcv广谱中和抗体的制备、检测以及应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201215

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20201210BHEP

Ipc: A61K 38/10 20060101ALI20201210BHEP

Ipc: A61K 38/16 20060101ALI20201210BHEP

Ipc: C07K 7/08 20060101AFI20201210BHEP

Ipc: C12N 15/11 20060101ALI20201210BHEP

Ipc: A61P 35/00 20060101ALI20201210BHEP

Ipc: C07K 14/00 20060101ALI20201210BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220929

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018047253

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1553972

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230415

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20230315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230615

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1553972

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230616

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230717

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018047253

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230315

26N No opposition filed

Effective date: 20231218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240115

Year of fee payment: 7

Ref country code: GB

Payment date: 20240119

Year of fee payment: 7